Clinical trial · Observational
A Real-World Study on Extranodal Lymphoma
NCT06573099CI-TRIAL-00080202not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Extranodal Lymphoma | Extranodal Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Lymphoma, B-Cell | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No interventions need to be specified for this study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression Free Survival (PFS)
- timeFrame
- Baseline up to data cut-off (up to approximately 1 year)
- description
- Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
Secondary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- Baseline up to data cut-off (up to approximately 1 year)
- description
- Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years (including 18 years old). 2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined. 3. Patients who have received systematic clinical treatment. 4. Patients with measurable lesions, at least containing one effective evaluation of efficacy. Exclusion Criteria: 1. Patients who only receive supportive treatment. 2. Patients who cannot obtain effective evaluation data of efficacy.
References
Publications (0)
Data not yet available
No reference posted for this study.